Efzofitimod Gets Fast Track Status for Pulmonary Sarcoidosis
Efzofitimod is a potential first-in-class selective modulator of neuropilin-2 that is designed to downregulate innate and adaptive immune responses in inflammatory disease states.
Respiratory Diseases/Disorders
Dexmedetomidine Cuts Perioperative Respiratory AEs in Tonsillectomy
Incidence of PRAEs reduced with dexmedetomidine versus midazolam among children undergoing tonsillectomy and adenoidectomy
Ensifentrine Improves Lung Function, Cuts COPD Exacerbations in Late Stage Trial
Ensifentrine (RPL554) is a first-in-class, dual phosphodiesterase (PDE) 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory actions.
OCS-Sparing Effect of Dupilumab for Severe Asthma Maintained
Oral corticosteroid dosage reduction sustained in open-label extension study of dupilumab
Asthma Drug Fluticasone Fails as Potential COVID-19 Treatment
Finding from a nationwide study of 5,000 participants that continues to evaluate existing drugs to treat mild-to-moderate COVID-19
Novel Oral Drug Combo Fast Tracked for Obstructive Sleep Apnea
The designation is supported by data from the phase 2 MARIPOSA study, which included adults with mild to moderate OSA.
Azithromycin Improves Outcomes in Poorly Controlled Child Asthma
Better control, fewer exacerbations seen with addition of oral azithromycin to standard therapy in children with poorly controlled asthma
Homeopathic Med Used for Snoring Recalled Due to Microbial Contamination
SnoreStop NasoSpray is a nasal spray used to temporarily help stop or reduce symptoms of nonapneic snoring.
Nasal Therapy Improves Symptoms, Inflammation in Patients With Chronic Sinusitis
OPN-375 is currently marketed under the brand name Xhance for the treatment of nasal polyps in patients 18 years of age and older.
Abatacept, Infliximab Improved Survival in Adults Hospitalized With COVID-19
The ACTIV-1 Immune Modulators trial was led by the NIH and enrolled 1971 hospitalized adults with moderate to severe COVID-19.
